PHARMACY BULLETIN 5 S W O R K S H O P. 5S comprised of a list of five Japanese. The Malaysian Administrative Modernisation and Management

Size: px
Start display at page:

Download "PHARMACY BULLETIN 5 S W O R K S H O P. 5S comprised of a list of five Japanese. The Malaysian Administrative Modernisation and Management"

Transcription

1 Pharmacy Department, Seri Manjung Hospital PHARMACY BULLETIN Drug & Poison Information Service / 2nd Edition 2014 INSIDE THIS ISSUE: 5S Workshop 1-2 Pharmacy Dept. Operating Hours & Contact No. Information on Xarelto (Rivaroxaban) Updates on MOH Formulary ADR Statistics of HSM Staff Information 10 5 S W O R K S H O P 5S comprised of a list of five Japanese words, i.e. Seiri (Sort), Seiton (Set in order), Seiso (Shine), Seiketsu (Standardize), and Shitsuke (Sustain). This 5S practice is one of the strategies that has been implemented by the Pharmacy facilities of KKM to establish convenient, organized and Advisor Mdm. Zahariah bt. Zainul Abideen Chief Editor Miss Noorsidah bt. Md. Yusoff Board of Editors Mr. Ahmad Firdaus b. Shamsuddin Miss Nurhazirah bt. Saridin Miss Nurul Hidayah bt. Jusoh Miss Yue Yoke Xin safe working environment that stimulates the culture of continuous development (Kaizen), which contributes towards enhancing the quality and productivity of Pharmacy. This practice was shown to reduce the risks in medication error while dispensing, therefore adapted in all Pharmacy facilities in KKM. The Malaysian Administrative Modernisation and Management Planning Unit (MAMPU) has taken initiatives to improve the implementation of 5S, which has been rebranded to Ekosistem Kondusif Sektor Awam (EKSA). This is consistent with the efforts to strengthen the organizational culture of high performance and innovative among public sector agencies through the provision of an environment, culture and values into practice. 1

2 On 24th May 2014, a 5S Workshop organized by Pharmacy Department was held at Dewan Mutiara, Seri Manjung Hospital with the objectives, 1) to develop the principles of 5S practice in general, 2) to guide the execution of 5S practice inside the public sector, and 3) to help instill 5S culture through internal audit. There were around 102 participants from various departments in Hospital Seri Manjung and Health Clinics in Manjung district. The lectures were delivered by Mr. Daniel Liew Ching Yien, a Pharmacist from Setapak Health Clinic who attended the Training of Trainers (TOT) EKSA Programme, organized by MAMPU in February The topics included were: 1) Introduction to EKSA, 2) Ethics in Auditing, and 3) Audit Procedures for EKSA. There was also an experience sharing session. 5S starts from home, and working place is our second home, says Mr. Daniel Liew, therefore the working area condition is critical to the morale of employees and the basis of customers first impressions. It is also important towards improving the effectiveness, efficiency and productivity in work. The workshop ended successfully with the closing speech by the Coordinator of 5S Programme, Mr. Gobi Hariyanayagam, followed by a visit to Satellite Pharmacy and Ward Supply Pharmacy. 2

3 Pharmacy Department Operating Hours & Contact No. OPERATING HOURS: CONTACT NO: Services: Outpatient Pharmacy Methadone Replacement Therapy (Methadone Clinic) Ward Supply Pharmacy Satellite Pharmacy TDM Pharmacy (Clinical Pharmacokinetic Service) CDR Pharmacy (Oncology Pharmacy) Drug & Poison Information Service (DPIS) Week Days (Monday Friday) 7.30am pm 7.00am am 5.00pm 7.00am 5.00pm 5.00pm 5.00pm Store Pharmacy 5.00pm Saturday, Sunday & Public Holiday 11.00am 7.00am am am am ON-CALL: After Office Hour (for toxic case & appointment case ONLY) Tel. No : Ext: Head of Department 6688 Outpatient Pharmacy 6683/6684/ 6686 Methadone Clinic 6937 Ward Supply Pharmacy 6687 DPIS 6691 Galenical 6693 CDR 6694 Satellite Pharmacy 6695 TDM 6696 Store Pharmacist 6698 Store (Drugs) 6702/6699 Store (Non-drugs) 6703/6700 After office hour of weekdays & 11.00am- 7.00am Saturday, Sunday & Public Holiday, the supply of medicines to patients from the emergency department, ward & discharge patients are conducted at the Satellite Pharmacy. 3

4 INFORMATION ON XARELTO (RIVAROXABAN) Xarelto 15mg film coated tablet Xarelto 20mg film coated tablet Currently Approved Indication in HSM: Treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. 3 DOSE: Switching patients with DVT or PE on VKA to Xarelto 1 For patients treated for DVT or PE or prevention of recurrent DVT and PE, treatment with Vitamin K antagonist (VKA) -Warfarin should be stopped To assess the residual effect of VKA closely monitor the international normalised ratio (INR) Xarelto therapy should be initiated when the INR is 2.5 Switching patients with DVT or PE on LMWH to Xarelto 1 Patients on anticoagulation therapy in the initial phase (first 21 days) 15 mg = First 3 weeks: One 15mg tablet, twice daily 20 mg= One 20 mg tablet, once daily as long as the risk persists 1 Xarelto should be administered as long as the risk of DVT/PE persists 1 A reduction of the dose from 20 mg once daily to 15 mg once daily in renally impaired patients should be considered if the patients assessed risk for bleeding outweighs the risk for recurrent DVT and PE 1 The duration of therapy should be individualised after careful assessment of the treatment benefit against the risk of bleeds Xarelto is not recommended as an alternative to UFH in patients with PE who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy Xerelto 15mg and 20mg tablets should be taken with food 1 CHARACTERISTICS Drug class Direct Factor Xa Inhibitor 1 Administration Oral 1 Patients on anticoagulation therapy for more than 21 days Bioavailability % For 15 mg and 20 mg when taken with food Half -life 5-9 h in young adults h in elderly patients 1 Time to peak plasma 2-4 hours 1 concentration Renal excretion as ~ 33 % 1 unchanged drug References: 1. Xarelto 15mg and 20mg Malaysia Product Insert, April Xarelto Dosing and Prescriber Guide Pamphlet, April Formulary FUKKM Bil 1/2014 4

5 MECHANISM OF ACTION Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of Factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated. Xarelto is contraindicated in case of 1 Hypersensitivity to the active substance or to any of the excipients Clinically significant active bleeding Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C Pregnancy and breast feeding Lesion or condition at significant active bleeding Concomitant treatment with any other anticoagulant agent except under the circumstances of switching therapy to or from Xarelto or when UFH is given at doses necessary to maintain a patent central venous or arterial catheter Xarelto is not recommended for use in patients 1 Below 18 years old of age With creatinine clearance < 15 ml/min Receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp such as azoleantimycotics ( ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitor (eg ritonavir) Co-administration with dronedarone (limited clinical data) References: 1. Xarelto 15mg and 20mg Malaysia Product Insert, April Xarelto Dosing and Prescriber Guide Pamphlet, April Formulary FUKKM Bil 1/2014 Benefits (Improving therapy adherence through) 1 : Oral administration Small, easy to swallow tablet Fixed dose No need for routine coagulation monitoring No dietary restrictions Low risk of drug- drug interactions Patients potentially at higher risk of bleeding 1 Patients with renal impairment due to potentially prolonged half life of Xarelto Patients with hepatic impairment Patients concomitantly receiving other medicinal products Patients with other haemorrhagic risk factors such as: Uncontrolled severe arterial hypertension Active ulcerative gastrointestinal disease Recent gastrointestinal ulcerations Vascular retinopathy Recent intracranial or intracerebral haemorrhage Intraspinal or intracerebral vascular abnormalities Recent brain, spinal or ophthalmological surgery Bronchiectasis or history of pulmonary bleeding Congenital or acquired bleeding disorders * Women of child-bearing potential should avoid becoming pregnant during treatment with Xarelto 1 5

6 UPDATES ON MOH FORMULARY (FUKKM 1/2014) 1. DRUGS NEWLY APPROVED FOR INCLUSION IN MOH FORMULARY NO GENERIC NAME PRESCRIBER CATEGORY 1 Lidocaine Medicated Plaster 5% w/w A* Pain Specialist Only APPROVED INDICATIONS For the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN). 2 Zonisamide 100mg tablet A* As adjunctive therapy in the treatment of partial seizures in adults with epilepsy. 3 Beclomethasone dipropionate 100mcg and formoterol fumarate dehydrate 6mcg pressurized inhalation solution A/KK 4 Dienogest 2mg tablet A/KK Treatment of endometriosis Regular treatment of asthma where use of a combination product ( inhaled corticosteroid and long acting beta2 agonist) is appropriate in: i) Patient not adequately controlled with inhaled corticosteroids and as needed inhaled short-acting beta2 agonist or ii) Patient already adequately controlled on both inhaled corticosteroids and long-acting beta2 agonists 5 Lactobacillus acidophilus 100 million viable cells and estriol 0.03mg vaginal tablet 6 Sodium glycerophosphate for addition into infusion solution, 20ml vial A/KK A i) Atrophic vaginitis due to estrogen deficiency during menopause and post-menopause, or as co-medication to systemic hormone replacement therapy. ii) Restoration of the Lactobacillus flora after local and/or systemic treatment with anti-infective agents or chemotherapeutic agents. Indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirement of phosphate. 7 1) Amlodipine besylate/valsartan/hydrochlorothiazide 5/160/12.5mg 2) Amlodipine besylate/valsartan/hydrochlorothiazide 10/160/12.5mg 3) Amlodipine besylate/valsartan/hydrochlorothiazide 10/160/25mg A/KK Treatment of essential hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension. 8 1) Everolimus 0.25mg tablet 2) Everolimus 0.75mg tablet A* Indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant in combination with ciclosporin for microemulsion and corticosteroids. 6

7 2. ADDITIONS AND AMENDMENTS OF FORMULATION / STRENGTH / PRESCRIBER CATEGORY/ DOSAGE FORM / INDICATION APPROVED FOR INCLUSION IN MOH FORMULARY ADDITIONS OF INDICATION NO GENERIC NAME ADD INDICATIONS 1 Nilotinib 150mg capsule 2 Salmeterol/fluticasone propionate 50/250mcg dry powder inhaler 3 Ivabradine 5mg & 7.5mg film coated tablet 4 Vildagliptin 50mg tablet Treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Regular treatment of COPD including chronic bronchitis and emphysema. 1) Symptomatic treatment of chronic stable angina pectoris in coronary artery disease patients with normal sinus rhythm. 2) Treatment of chronic heart failure NYHA II to IV class with sinus rhythm and whose heart rate is 75bpm. 1) As a monotherapy in type 2 DM patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. 2) An adjunct to diet and exercise to improve glycaemic control in type 2 DM patients: as a dual therapy in combination with insulin in patients with insufficient glycaemic control. NO AMENDMENTS OF PRESCRIBER CATEGORY NO GENERIC NAME OLD CATEGORY 1 Irbesartan 300mg/ HCTZ 12.5mg tablet 2 Montelukast sodium 10mg tablet 3 Celecoxib 200mg capsule 4 Simvastatin 10mg, 20mg and 40mg tablet ADDITIONS OF STRENGTH EXISTING DRUG IN FORMULARY ADD STRENGTH 1 Nilotinib 200mg capsule Nilotinib 150mg capsule 2 Propofol 10mg/ml (1%) emulsion for injection of infusion 3 Clostridium botulinum Type A toxin haemagglutinin complex 500U/vial powder for injection NEW CATEGORY A* A/KK A* A/KK A* A A/KK B Propofol 20mg/ml (2%) emulsion for injection of infusion Clostridium botulinum Type A toxin haemagglutinin complex 300U/vial powder for injection 5 Triptorelin acetate 3.75mg injection Genital and extragenital endometriosis (stage I to stage IV). DRUG APPROVED TO BE REMOVED FROM FORMULARY NO GENERIC NAME REASON ALTERNATIVE 1 Lovastatin 20mg tablet Low total utility score in statin group Simvastatin 10mg, 20mg & 40mg tablet 7

8 No. of Reports < 1 1 to 6 7 to > 60 No. of Reports ADVERSE DRUG REACTION STATISTICS OF SERI MANJUNG HOSPITAL (2013) Adverse Drug Reaction (ADR) is defined as a response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function. ADR are classified into six types: dose related, non-dose related and time-related, time related, withdrawal, and failure of therapy. The management of ADR includes withdrawal of the drug if possible and specific treatment of its effects. In 2013, there were 189 suspected ADR cases reported to Pharmacy Department in Seri Manjung Hospital. DEMOGRAPHIC DATA OF REPORTED CASES AGE OF ADR AFFECTED PATIENTS Age Category (Years) GENDER OF ADR AFFECTED PATIENTS RACE OF ADR AFFECTED PATIENTS Female 49.74% = 94 Male 50.26% = Malay Chinese Indian Others Race 8

9 Pharmacological Group System Organ Class CATEGORY OF ADR REPORTERS SEVERITY OF ADR REPORTS Medical Officer 5.82% = 11 Pharmacist 94.18% = 178 Moderate 49.74% = 94 Severe 12.70% = 24 Mild 37.57% = 71 ADVERSE DRUG REACTION BY SYSTEM ORGAN CLASS SKIN AND APPENDAGES DISORDERS. 66.7% BODY AS A WHOLE - GENERAL DISORDERS 17.5% RESPIRATORY SYSTEM DISORDERS GASTRO - INTESTINAL SYSTEM DISORDERS CENTRAL AND PERIPHERAL NERVOUS SYSTEMS DISORDERS 3.2% 1.6% 4.8% APPLICATION SITE DISORDERS MUSCULO - SKELETAL SYSTEM DISORDERS LIVER AND BILIARY SYSTEM DISORDER URINARY SYSTEM DISORDERS HEART RATE AND RHYTHM DISORDERS VISION DISORDERS PLATELET, BLEEDING & CLOTTING DISORDERS WHITE CELL AND RES DISORDERS 1.6% No. of Reports ANTIINFECTIVES ANALGESIC COMBINATION ANTIEPILEPTIC CARDIOVASCULAR ANTIGOUT OTHERS ANTICOAGULANT TRADITIONAL MEDICINE EYE PREPARATIONS ANTIEMETIC ANTIULCER ANTIPSYCHOTIC ANTIHYPERLIPIDEMIC ANTIVENOM ANTISPASMODIC ANTIHISTAMINE CONTRAST MEDIA CORTICOSTEROID ANTIASTHMATIC ANTIVIRAL ANTITUBERCULOSIS SUSPECTED ADR-CAUSING DRUG BY PHARMACOLOGICAL GROUP ANTIDIABETIC VACCINE 7.4% 4.2% 3.7% 3.2% 2.6% 2.6% 2.1% 1.6% 24.9% 38.1% No. of Reports 9

10 STAFF INFORMATION 11 MARCH 2014 MISS HAMIMAH BT ABD RAZAK (PEMBANTU AWAM H11) MISS SITI NURUL IDAYU BT MOHD ROSEDI (PEMBANTU AWAM H11) 19 MAY 2014 MISS SYAKIRAH BT KHAIRUDDIN (PEGAWAI FARMASI PROVISIONAL U41) MISS NGIENG HSERN LIN (PEGAWAI FARMASI PROVISIONAL U41) MISS WONG SIEN YIH (PEGAWAI FARMASI PROVISIONAL U41) 16 JUNE 2014 MISS KUMALATHA A/P PRASAD (PEGAWAI FARMASI PROVISIONAL U41) 7 MAY 2014 MADAM ANIS BT AHMAD PUAZIL (PEGAWAI FARMASI PROVISIONAL U41) 19 MAY 2014 MR CHOONG CHIE WENG (PEGAWAI FARMASI U41) 5 JUNE 2014 MADAM NEETHIAVATHI A/P SUBRAMANIAM (PEMBANTU TADBIR N22) 11 APRIL 2014 MADAM ZAWIAH BT ZAINAL (PEGAWAI FARMASI U54) 16 MAY 2014 MISS NURUL ZUHANIS BT MOHAMED (PEGAWAI FARMASI U41) 10

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as

More information

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your

More information

Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust.

Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. This Patient Group Direction (PGD) has been written

More information

XARELTO (RIVAROXABAN) PRESCRIBER GUIDE

XARELTO (RIVAROXABAN) PRESCRIBER GUIDE XARELTO (RIVAROXABAN) PRESCRIBER GUIDE Prescribing information found on pages 16-17 This guide is to be used to support the appropriate use of Xarelto in the following indications: Prevention of stroke

More information

XARELTO (RIVAROXABAN) PRESCRIBER GUIDE

XARELTO (RIVAROXABAN) PRESCRIBER GUIDE XARELTO (RIVAROXABAN) PRESCRIBER GUIDE Prescribing information found on pages 22-23 This guide is to be used to support the appropriate use of Xarelto in the following indications: Prevention of stroke

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

Xarelto (rivaroxaban) Prescriber Guide November 2012

Xarelto (rivaroxaban) Prescriber Guide November 2012 Xarelto (rivaroxaban) Prescriber Guide November 2012 Simple Protection for More Patients 2 Xarelto Prescriber Guide Patient Alert Card 4 Dosing Recommendations 4 Dosing in patients with atrial fibrillation

More information

XARELTO (RIVAROXABAN) EDUCATIONAL PACK FOR 15MG AND 20MG DOSING

XARELTO (RIVAROXABAN) EDUCATIONAL PACK FOR 15MG AND 20MG DOSING XARELTO (RIVAROXABAN) EDUCATIONAL PACK FOR 15MG AND 20MG DOSING NOW UPDATED A N D I N C L U D E S A NEW INDICATION Prevention of stroke and systemic embolism in eligible adult patients with non-valvular

More information

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016

More information

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach. Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight

More information

Xarelto (rivaroxaban) Prescriber Guide

Xarelto (rivaroxaban) Prescriber Guide Xarelto (rivaroxaban) Prescriber Guide Simple Protection For More Patients 2 Xarelto Prescriber Guide Patient Alert Card 4 Dosing Recommendations 4 Dosing in patients with atrial fibrillation 4 Patients

More information

Birmingham, Sandwell and Solihull Cardiac and Stroke Network. Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement

Birmingham, Sandwell and Solihull Cardiac and Stroke Network. Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement Birmingham, Sandwell and Solihull Cardiac and Stroke Network Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement Introduction This guidance informs prescribers and commissioners

More information

Xarelto (rivaroxaban) Prescriber Guide

Xarelto (rivaroxaban) Prescriber Guide Xarelto (rivaroxaban) Prescriber Guide Patient Alert Card A patient alert card must be provided to each patient who is prescribed Xarelto 15 or 20 mg, and the implications of anticoagulant treatment should

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants

More information

Dorset Cardiac Centre

Dorset Cardiac Centre P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February

More information

Xarelto (rivaroxaban) Prescriber Guide

Xarelto (rivaroxaban) Prescriber Guide Xarelto (rivaroxaban) Prescriber Guide May 2013 Simple Protection for More Patients 2 Xarelto Prescriber Guide Patient Alert Card 4 Dosing Recommendations 4 Dosing in patients with atrial fibrillation

More information

Pathway for the management of DVT in primary Care

Pathway for the management of DVT in primary Care Pathway for the management of DVT in primary Care Final Version: Approved by NHS DGS CCG: June 2015 This document aims to support practices in DGS CCG in the Management & Treatment of patients with suspected

More information

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions

More information

Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists

Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists Traffic light classification- Amber 2 specialist initiation Information sheet for Primary Care Prescribers

More information

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications

More information

Anticoagulant therapy

Anticoagulant therapy Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in

More information

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about

More information

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Implementation of NICE TA 261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Contents 1. Executive summary 2. Introduction

More information

Dorset Medicines Advisory Group

Dorset Medicines Advisory Group Shared Care Guideline for prescribing rivaroxaban in the prevention of adverse outcomes after acute management of acute coronary syndrome in adults INDICATION In accordance with NICE TA335 rivaroxaban

More information

Practical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준

Practical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준 Practical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준 Contents Converting to/from rivaroxaban Measuring levels of rivaroxaban Patients potentially at higher risk of bleeding Renal

More information

FDA Approved Oral Anticoagulants

FDA Approved Oral Anticoagulants FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic

More information

Drug name: RIVAROXABAN (Xarelto ) For the treatment of acute venous thromboembolism in adult patients.

Drug name: RIVAROXABAN (Xarelto ) For the treatment of acute venous thromboembolism in adult patients. Drug name: RIVAROXABAN (Xarelto ) For the treatment of acute venous thromboembolism in adult patients. DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name : Date of Birth:

More information

Uncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser

Uncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser Acute Sector NHS Grampian Staff Local Treatment Protocol For Venous Thromoboembolic Prophylaxis Using Rivaroxaban 10mg Tablets In Adult Patients Undergoing Elective Hip Or Knee Replacement Surgery. Lead

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE June 22, 2015 SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical

More information

The Prescribing pathway consists of a number of parts:

The Prescribing pathway consists of a number of parts: NHS EAST LANCASHIRE CCG & NHS BLACKBURN WITH DARWEN CCG DVT Primary Care Prescribing Pathway www.elmmb.nhs.uk Introduction www.elmmb.nhs.uk Version 1.2/January 2013 Introduction Blackburn with Darwen and

More information

Updates to the Alberta Human Services Drug Benefit Supplement

Updates to the Alberta Human Services Drug Benefit Supplement Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone

More information

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Relevant Licensed Indications

More information

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

Updates to the Alberta Drug Benefit List. Effective January 1, 2016 Updates to the Alberta Drug Benefit List Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)

More information

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Amber Drug Level 2 Leeds We have started your patient on rivaroxaban for the treatment of provoked VTE (deep

More information

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small

More information

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban

More information

New Oral Anticoagulants. How safe are they outside the trials?

New Oral Anticoagulants. How safe are they outside the trials? New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants

More information

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis. DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

More information

East Kent Prescribing Group

East Kent Prescribing Group East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal

More information

Xarelto Accurate Dosing Matters

Xarelto Accurate Dosing Matters Xarelto Accurate Dosing Matters Prevention of Stroke and Systemic Embolism in adults with nonvalvular Atrial Fibrillation with one or more risk factors a 20 mg 15 mg Patients with CrCl > 49 ml/min with

More information

Xarelto Accurate Dosing Matters

Xarelto Accurate Dosing Matters Xarelto Accurate Dosing Matters Prevention of Stroke and Systemic Embolism in adults with nonvalvular Atrial Fibrillation with one or more risk factors a 20 mg OD 15 mg OD Patients with CrCl > 49 ml/min

More information

Implementation of NICE TAs 261 and 287

Implementation of NICE TAs 261 and 287 Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group Northampton General Hospital NHS Trust Northamptonshire Healthcare Foundation Trust Implementation

More information

More information for patients and caregivers can be accessed at http://www.xarelto-us.com/.

More information for patients and caregivers can be accessed at http://www.xarelto-us.com/. Janssen Research & Development Submits Application to U.S. FDA for XARELTO (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome RARITAN, DECEMBER 29, 2011 -

More information

Oral Anticoagulants: What s New?

Oral Anticoagulants: What s New? Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center syoung1@hmc.psu.edu August 2012 Oral Anticoagulant

More information

DABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN

DABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)

More information

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

Analytical Specifications RIVAROXABAN

Analytical Specifications RIVAROXABAN Page 1 of 9 ANALYTE NAME AND STRUCTURE - RIVAROXABAN SYNONYMS Xarelto CATEGORY Anticoagulant TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND Xarelto (rivaroxaban) is an orally

More information

TSOAC Initiation Checklist

TSOAC Initiation Checklist Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.

More information

Traditional anticoagulants

Traditional anticoagulants TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University

More information

VOLUME No: 21 04 written by Sara Wilds & Kathryn Buchanan. Date of issue: June 2012 (updated November 2012 following NICE TA 256)

VOLUME No: 21 04 written by Sara Wilds & Kathryn Buchanan. Date of issue: June 2012 (updated November 2012 following NICE TA 256) Prescribing Points A NEWSLETTER FOR ALL HEALTH CARE PROFESSIONALS IN OXFORDSHIRE, WRITTEN BY THE MEDICINES MANAGEMENT TEAM, OXFORDSHIRE PCT, JUBILEE HOUSE, OXFORD BUSINESS PARK SOUTH, OXFORD, OX4 2LH.

More information

Management for Deep Vein Thrombosis and New Agents

Management for Deep Vein Thrombosis and New Agents Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular

More information

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /

More information

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy ~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:

More information

Volume 7; Number 19 November 2013

Volume 7; Number 19 November 2013 Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs? Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning A Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning Drugs to Prevent Abnormal Blood

More information

Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation.

Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation. South West Essex Rivaroxaban Shared Care Guideline (SCG) Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation. Introduction

More information

News Release. Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com

News Release. Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com News Release Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com Shaun Mickus Phone: 908.927.2416 Mobile: 973.476.7144 smickus@its.jnj.com Investor contacts: Stan

More information

Xarelto (rivaroxaban) Prescriber Guide

Xarelto (rivaroxaban) Prescriber Guide Xarelto (rivaroxaban) Prescriber Guide January 2015 Patient Alert Card 04 Dosing Recommendations 04 Dosing in patients with atrial fibrillation 04 Patients with renal impairment 04 Duration of therapy

More information

Introduction. Background to this event. Raising awareness 09/11/2015

Introduction. Background to this event. Raising awareness 09/11/2015 Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness

More information

Dabigatran (Pradaxa) Guidelines

Dabigatran (Pradaxa) Guidelines Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without

More information

New Anticoagulants: When and Why Should I Use Them? Disclosures

New Anticoagulants: When and Why Should I Use Them? Disclosures Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia

More information

Shared Care Guideline between Trusts and CCGs. Drug name: RIVAROXABAN (Xarelto ) For the treatment of acute venous thromboembolism in adult patients.

Shared Care Guideline between Trusts and CCGs. Drug name: RIVAROXABAN (Xarelto ) For the treatment of acute venous thromboembolism in adult patients. Shared Care Guideline between Trusts and CCGs Drug name: RIVAROXABAN (Xarelto ) For the treatment of acute venous thromboembolism in adult patients. DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND

More information

Breadth of indications matters One drug for multiple indications

Breadth of indications matters One drug for multiple indications Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:

More information

Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.

Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D. Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical

More information

Indication: Indication: Protaxos is indicated in adults.

Indication: Indication: Protaxos is indicated in adults. Maklumat tambahan indikasi untuk upload pada laman web Year 2013 Products Approved For Additional Indication (DCA 262 28 Mac 2013) NO PRODUCT (ACTIVE INGREDIENT) 1. 1.1 EVISTA TABLET 60MG [ Raloxifene

More information

Volume 7; Number 15 August 2013

Volume 7; Number 15 August 2013 Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire

More information

Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare

Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:

More information

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:

More information

Comparison between New Oral Anticoagulants and Warfarin

Comparison between New Oral Anticoagulants and Warfarin Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several

More information

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime

More information

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis

More information

Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )

Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR

More information

Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )

Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals

More information

Xarelto (rivaroxaban) Prescriber Guide

Xarelto (rivaroxaban) Prescriber Guide Xarelto (rivaroxaban) Prescriber Guide Patient Alert Card Dosing Recommendations Dosing in patients with atrial fibrillation Patients with renal impairment Duration of therapy Missed dose Dosing in the

More information

Experience matters: Practical management in your hospital

Experience matters: Practical management in your hospital Experience matters: Practical management in your hospital Dr AGG Turpie McMaster University, Hamilton, ON, Canada Disclosures AGG Turpie has acted as a consultant for Bayer HealthCare, Janssen, Sanofi-Aventis,

More information

Newer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013

Newer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013 Newer Anticoagulants and Newer Diabetic Drug Classes Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013 Apixaban Newer Anticoagulants Dabigatran etexilate Rivaroxaban

More information

Oxford Anticoagulation & Thrombosis Service Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Oxford Anticoagulation & Thrombosis Service Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Oxford University Hospitals NHS Trust Oxford Anticoagulation & Thrombosis Service Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Information for people with a blood clot (thrombus) What is this

More information

rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC

rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC 13 January 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS

More information

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart

More information

Xarelto (Rivaroxaban)

Xarelto (Rivaroxaban) Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,

More information

Xarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason

Xarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason Xarelto (Rivaroxaban): Effective in a broad spectrum Joep Hufman, MD Medical Scientific Liason Xarelto : Effective in a broad spectrum Introduction Therapeutic areas SPAF VTE Prevention VTE treatment Practical

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic

More information

Anticoagulants in Atrial Fibrillation

Anticoagulants in Atrial Fibrillation Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives

More information

2. Background This indication of rivaroxaban had not previously been considered by the PBAC.

2. Background This indication of rivaroxaban had not previously been considered by the PBAC. PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15mg and 20mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: March 2013 1. Purpose of Application The application requested the

More information

Title Use of rivaroxaban in suspected DVT in the Emergency Department Standard Operating Procedure. Author s job title. Pharmacist.

Title Use of rivaroxaban in suspected DVT in the Emergency Department Standard Operating Procedure. Author s job title. Pharmacist. Document Control Title Use of rivaroxaban in suspected DVT in the Emergency Department Author Pharmacist Directorate Clinical Support Services Version Date Issued Status 0.1 Oct Draft 2015 1.0 Dec Final

More information

Rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery

Rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery for preventing venous thromboembolism after hip or knee replacement surgery (riv-ah-rocks-ah-ban) Summary Rivaroxaban is an oral anticoagulant and the first direct factor Xa inhibitor. Rivaroxaban has

More information

Safety Information Card for Xarelto Patients

Safety Information Card for Xarelto Patients Safety Information Card for Xarelto Patients 15mg Simply Protecting More Patients 20mg Simply Protecting More Patients Keep this card with you at all times Present this card to every physician or dentist

More information

PHARMACOLOGY UPDATE: BOOMER DRUGS

PHARMACOLOGY UPDATE: BOOMER DRUGS PHARMACOLOGY UPDATE: BOOMER DRUGS Sandra Brownstein, PharmD Evercare Clinical Pharmacy Director West Region Objectives: Review the new drugs that have recently been approved by the FDA Determine the role

More information

Venous Thromboembolic Treatment Guidelines

Venous Thromboembolic Treatment Guidelines Venous Thromboembolic Treatment Guidelines About the NYU Venous Thromboembolic Center (VTEC) The center s mission is to deliver advanced screening, detection, care, and management services for patients

More information

**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011

**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011 Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both

More information

New Oral Anticoagulants

New Oral Anticoagulants New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.

More information

Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto )

Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto ) Guideline [Optional heading here. Change font size to suit] Document Number # QH-GDL-950:2014-2 Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto ) 1.

More information

The author has no disclosures

The author has no disclosures Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author

More information

Novel Oral Anticoagulants (NOACs) Prescriber Update 2013

Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg

More information

Living with a Non-Vitamin K Antagonist Oral Anticoagulant (NOAC)

Living with a Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) Living with a Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) dabigatran (Pradaxa ) rivaroxaban (Xarelto ) apixaban (Eliquis ) Information for patients Produced and made available by the Western Australian

More information